Replies to post #125591 on Biotech Values

[biomaven0]

Thanks for finding that.

I really don't see reduced osteoclastic activity in late-stage patients without known bone mets as concerning at all. It's cerainly plausible these patients have occult bone mets which haven't yet shown up on a scint scan. Be nice to know if their pre-treatment CTx levels were elevated.

http://journals.lww.com/corr/Abstract/2003/10001/Diagnosis_of_Occult_Bone_Metastases__Positron.16.aspx

Peter

[projectchris]

phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9OTY0OTR8Q2hpbGRJRD0tMXxUeXBlPTM=&t=1

Page 25 of the investor briefing describes hemoglobin changes across all tumor types. Exelixis did a poor job of highlighting this point on title of this page.----I could be mistaken but believe that is what I heard from the webcast accompanying slides.